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COM M E N TA RY

Pharmacogenomic testing

Enhancing personalized medication use for patients
Catrina M. Loucks MSc PhD Gabriella Groeneweg MA Carl Roy David K. Lee Michael J. Rieder MD PhD
Denis Lebel MSc FCSHP Shinya Ito MD FRCPC Colin J. Ross MSc PhD Bruce C. Carleton PharmD FCP FISPE

A

dverse drug reactions (ADRs) are an important
clinical problem in modern medicine, sometimes
resulting in debilitating and lethal consequences
for patients. The burden of ADRs in Canada is underemphasized owing to most ADRs going unreported.1
However, a 1998 study suggests that ADRs are between
the fourth and sixth leading cause of death of hospitalized patients in the United States.2 Genomic factors play a
key role in drug response and contribute substantially to
the risk of drug-induced harm. Pharmacogenomics—the
determination of the genomic predisposition to a certain
response to medication—is a key component in understanding how to use medication in a safer and more
effective manner. Pharmacogenomic testing allows for
the detection of genomic factors linked to differences in
drug response before treatment, ensuring that the benefit of a medication is maximized without the unintended
consequences of ADRs. While medication use in clinical
practice is already personalized by considering clinical
factors that contribute to variable drug responses, pharmacogenomic testing can explain why some patients
experience unusual responses to medication and further
enhances personalized medication use.
The Canadian Pharmacogenomics Network for Drug
Safety (CPNDS), 3 a group focused on incorporating
pharmacogenomics into clinical practice, has identified genomic factors responsible for a number of ADRs,
including but not limited to codeine-induced death in
breastfed infants,4,5 cisplatin-induced ototoxicity,6,7 and
anthracycline-induced cardiotoxicity. 8-10 To address
these serious ADRs, pharmacogenomic tests have been
developed to assess a given patient’s risk of experiencing an ADR. Clinical practice guidelines have also
been created to help clinicians develop better personalized therapy plans based on genomic risk.11-13 As more
genomic risk factors for ADRs are identified, pharmacogenomic testing can be optimized to provide better
risk-benefit profiling for each patient.

The CPNDS and childhood cancer treatment
The CPNDS has worked to incorporate pharmacogenomic testing into childhood cancer treatment decisions to reduce the risk of developing ADRs such as
anthracycline-induced cardiotoxicity. Anthracyclines,
the most frequently used chemotherapeutic drug in
Canada, can cause cardiac dysfunction leading to congestive heart failure in up to 20% of treated children.13
Based on clinical factors alone, the predicted risk of

experiencing this cardiac dysfunction (cardiotoxicity)
generally falls in the range of a few percent to an almost
100% chance. Incorporating pharmacogenomic testing
helps to better determine a patient’s specific risk before
treatment initiation. For instance, in 2 patients with the
same diagnosis, one patient’s genomic risk of serious
cardiotoxicity might be below 20%, whereas the second
patient’s risk might be greater than 80%. Importantly,
this ability to quantify pharmacogenomic risk provides
a vehicle for patients and their families to dictate the
level of risk they are comfortable with, in the paradigm
of benefit-risk decision making in their cancer treatment. This exemplifies patient-oriented care, where an
estimated risk of serious drug-induced cardiotoxicity of
less than 20% might be acceptable given the considerable mortality that accompanies many cancer diagnoses. However, a predicted risk of drug-induced harm of
more than 80% should require discussion of viable alternatives and pre-emptive preventive therapy. Together,
this allows for better profiling for each patient to make
informed treatment decisions.

Changes to drug labels
The CPNDS is not the only group focused on finding
drug safety solutions through pharmacogenomics. Both
the US Clinical Pharmacogenetics Implementation
Consortium14 and the Dutch Pharmacogenetics Working
Group15 also promote the use of pharmacogenomic information to enhance clinical decision making. The CPNDS
found that the use of codeine for postpartum pain management in mothers with an extra copy of the cytochrome P450 2D6 isozyme gene (CYP2D6) can be lethal
for their breastfed infants.5 These findings have led to
warnings and drug label changes by Health Canada, the
US Food and Drug Administration (FDA), the European
Medicines Agency, and the Pharmaceuticals and Medical
Devices Agency in Japan. Importantly, this research led
to changes in the use of codeine worldwide.11,15,16
Pharmacogenomic information to inform clinical
practice is included on more than 750 drug labels worldwide (https://www.pharmgkb.org/labels), a number
that continues to rise as more pharmacogenomic discoveries are made. Currently, the FDA provides pharmacogenomic information on 335 drug labels, while
Health Canada has been slower to incorporate such
information (included in 105 labels). Given that drugs
are used across all medical disciplines, pharmacogenomics should be the highest of priorities in both patient
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care advancement and federal investment in research.
To this end, the FDA facilitates the application of pharmacogenomics in clinical practice through initiatives
driven by the Genomics and Targeted Therapy Group. A
similar approach could be adopted by Health Canada as
a first step toward improving awareness of pharmacogenomic information to guide prescribing decisions for
Canadian physicians.

Integrating pharmacogenomic testing into
clinical practice
Clinicians who want to integrate pharmacogenomic testing into their practices face considerable challenges that
limit access. We propose an approach where pharmacogenomic testing is conducted only when a particular
drug is being considered for treatment. The inclusion of
only pharmacogenomic variants with clinical relevance,
such as those appearing on drug labels or in pharmacogenomic clinical practice guidelines, or those replicated in at least 3 independent populations with strong
associations (ie, odds ratios ≥ 3), allows for immediate
and evidence-based application to prescribing decisions.
Another possible avenue to improve accessibility is a
screening approach where comprehensive pharmacogenomic information is collected and readily available for
future prescribing decisions. This is an attractive strategy given the ever increasing affordability of genetic testing, and likely represents the future of pharmacogenomic
testing,17 but has obstacles for successful implementation.
A pharmacogenomic screening approach must adhere
to criteria outlined by Wilson and Jungner18 that have
been adapted to guide genomic screening approaches,19
with particular emphasis placed on providing strong evidence for improved patient outcomes and cost effectiveness through formal program evaluations. Furthermore,
deciding which variants should be reported and maintaining an updated list of variants with clinical relevance
will require ongoing resources and management of the
genomic data collected from screening.

Limitations of the health care system
Perceived resource constraints within the Canadian
health care system might threaten adoption of pharmacogenomic testing. We therefore propose prioritizing serious ADRs where delays in access to tests put
patients at risk of devastating consequences that also
represent substantial cost burdens on the health care
system. Pharmacogenomic testing for serious ADRs also
holds the most promise for cost effectiveness. We have
shown that cost savings associated with the prevention of one such ADR, anthracycline-induced cardiotoxicity, are predicted to outweigh the costs of testing.20
Specifically, severe cases of anthracycline-induced cardiotoxicity cost more than $1 million owing to the need
for heart transplants,20 and incorporation of pharmacogenomic testing is estimated to save $495 per patient,
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representing a 5.7% reduction in costs associated with
anthracycline-based cancer treatment.20
Several parameters must be optimized to improve
access for our proposed approach to pharmacogenomic
testing, including turnaround time for return of results;
integration of sample collection and return of results into
linic flow; and availability of pharmacogenomics training.
By prioritizing serious ADRs, such as those encountered
in childhood cancer treatment, the CPNDS is gaining
understanding of how best to deliver pharmacogenomic
testing to suit the needs of physicians, patients, and
families, while also assessing the effect of such testing
on the Canadian health care system by formally evaluating cost effectiveness. Importantly, lessons learned from
these experiences will help family physicians incorporate pharmacogenomic testing for additional serious
ADRs in the future. In particular, clinically relevant pharmacogenomic information informs the risk of experiencing the many serious ADRs encountered as a result
of analgesics (eg, codeine- or tramadol-induced central
nervous system depression or death), antibiotics (eg,
rifampin-isoniazid-pyrazinamide–induced liver injury),
and psychotropic medications (eg, carbamazepine- or
phenytoin-induced skin reactions) that are commonly
prescribed by family physicians. Given that these serious ADRs are typically rare, ordering pharmacogenomic
testing will allow family physicians to continue prescribing highly effective drugs with well understood safety
profiles in patients determined to be at low risk of experiencing ADRs, while choosing alternative drugs and
avoiding potential harm in patients at high risk.

Conclusion
Ultimately, increasing accessibility to pharmacogenomic
tests means better profiling risks of therapy before therapy begins and provides the potential to drastically affect
the use of medication by making it safer, more effective,
and personalized. It is an ethical responsibility for all of
us—clinicians, hospital administrators, and policy makers—to provide access to this service to all Canadian
families to help prevent serious ADRs when battling diseases and illnesses that require medication.
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